The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms. Traditional methods, such as hybridoma technology, can be time-intensive and limited in diversity. In response, Biointron has developed AbDrop™, a microfluidic, droplet-based single B cell screening platform designed to accelerate and enhance antibody discovery.
Unlike conventional approaches, AbDrop™ directly screens naturally matured individual B cells, maximizing CDR diversity by mining the entire plasma cell repertoire. This high-throughput system enables rapid identification of natively paired sequences, significantly reducing the discovery timeline to just 2–3 months.
This white paper outlines how AbDrop™ streamlines antibody discovery, providing an efficient, scalable, and precise solution for biopharmaceutical innovation.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express the protein of interest at desired levels. This case study illustrates the successful generation of a tag-free vaccine protein.
Biointron has developed our own CHOK1-Fut8KO expression platform for afucosylated antibodies.
Biointron established a single-B cell antibody discovery platform based on microfluidic technology. Combined with our proprietary fast antibody expression platform, it has been proven to be fast and efficient in many projects.
ScientistとScience Exchangeとのご利用可能です。
